Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels

Fertility and Sterility

Volumn 89, Issue 4, 2008, Pages 899-906

  Panidis, Dimitrios ^a   Farmakiotis, Dimitrios ^a   Rousso, David ^a   Kourtis, Anargyros ^a   Katsikis, Ilias ^a   Krassas, Gerassimos ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b PANAGIA GENERAL HOSPITAL   (Greece)

Author keywords

diet; Orlistat; PCOS

Indexed keywords

ANDROGEN; FOLLITROPIN; GLUCOSE; HYDROXYPROGESTERONE; INSULIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROLACTIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TETRAHYDROLIPSTATIN;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CALORIC RESTRICTION; CLINICAL ARTICLE; CONTROLLED STUDY; DIET THERAPY; FEMALE; HORMONE DETERMINATION; HUMAN; INSULIN RESISTANCE; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; WEIGHT REDUCTION;

17-ALPHA-HYDROXYPROGESTERONE; ANDROGENS; ANDROSTENEDIONE; ANTI-OBESITY AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; CALORIC RESTRICTION; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; DEHYDROEPIANDROSTERONE SULFATE; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; INSULIN; INSULIN RESISTANCE; LACTONES; LUTEINIZING HORMONE; OBESITY; POLYCYSTIC OVARY SYNDROME; PROLACTIN; PROSPECTIVE STUDIES; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 41749107754     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2007.04.043     Document Type: Article

References (46)

1. Sharpe R.M., and Franks S. Environment, lifestyle and fertility - an inter-generational issue. Nat Cell Biol Suppl 4 (2002) s33-s40
2. Franks S. 1995 Polycystic ovary syndrome. N Engl J Med 333 (1995) 853-861
3. Lobo R.A. What are the key features of importance in polycystic ovary syndrome?. Fertil Steril 80 (2003) 259-261
4. Ehrmann D. Polycystic ovary syndrome. N Engl J Med 352 (2005) 1223-1236
5. Azziz R., Ehrmann D., Legro R.S., Whitcomb R.W., Hanley R., Fereshetian A.G., et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 86 (2001) 1626-1632
6. Legato M.J. Gender-specific aspects of obesity. Int J Fertil Womens Med (1997) 184-197
7. Bjontorp P. Abdominal obesity and the metabolic syndrome. Ann Med 24 (1992) 465-468
8. Dunaif A., Futterweit W., Segal K.R., and Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in the polycystic ovary syndrome. Diabetes 38 (1989) 1165-1174
9. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18 (1997) 774-780
10. Goodarzi M.O., and Korenman S.G. The importance of insulin resistance in polycystic ovary syndrome. Fertil Steril 80 (2003) 255-258
11. Nestler J.E., and Jakubowicz D.J. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 82 (1997) 4075-4079
12. Nestler J.E., Powers L.P., Matt D.W., Steingold K.A., Plymate S.R., Rittmaster R.S., et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 72 (1991) 83-89
13. Deslypere J.P., Verdonck L., and Vermeulen A. Fat tissue: a steroid reservoir and site of steroid metabolism. J Clin Endocrinol Metab 61 (1985) 564-570
14. Peltoketo H., Luu-The V., Simard J., and Adamski J. 17ß-Hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes. J Mol Endocrinol 23 (1999) 1-11
15. Norman R.J., Davies M.J., Lord J., and Moran L. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 13 (2002) 251-257
16. Hoeger K. Obesity and weight loss in polycystic ovary syndrome. Obstet Gynecol Clin North Am 28 (2001) 85-97
17. Kiddy D.S., Hamilton-Fairley D., Bush A., Short F., Anyaoku V., Reed M.J., et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 36 (1992) 105-111
18. Clark A.M., Ledger W., Galletly C., Tomlinson L., Blaney F., Wang X., et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 10 (1995) 2705-2712
19. Holte J., Bergh T., Gennarelli G., and Wide L. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotriophins and sex steroid hormones in premenopausal women. Clin Endocrinol (Oxf) 41 (1994) 473-481
20. Huber-Buchholz M.M., Carey D.G.P., and Norman J. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 84 (1999) 1470-1474
21. Moran L.J., Noakes M., Clifton P.M., Tomlinson L., and Norman R.J. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 812-819
22. Pasquali R., Antenucci D., Casimirri F., Venturoli S., Paradisi R., Fabbri R., et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 68 (1989) 173-179
23. Kiddy D.S., Hamilton Fairley D., Seppala M., Koistinen R., James V.H., Reed M.J., et al. Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries: correlation with serum insulin and insulin-like growth factor-I. Clin Endocrinol (Oxf) 31 (1989) 757-763
24. Clark A.M., Thornley B., Tomlinson L., Galletley C., and Norman R.J. Weight loss in obese women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod 13 (1998) 1502-1505
25. Andersen P., Seljeflot I., Abdelnoor M., Arnesen H., Dale P.O., Levik A., et al. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 44 (1995) 611-616
26. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 21 Suppl 3 (1997) S12-S23
27. Dren M.L., and Van der Veen E.A. Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes 17 (1993) 241-244
28. Sjöström L., Rissanen A., and Andersen T. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 352 (1998) 167-172
29. Davidson M.H., Hauptman J., DiGirolamo M., Foreyt J.P., Halsted C.H., Heber D., et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281 (1999) 235-242
30. Tonstad S., Pometta D., and Erkelens D.W. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidemias. Eur J Clin Pharmacol 46 (1994) 405-410
31. Rössner S., Sjöström L., Noack R., Meinders E., and Nosedall. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 8 (2000) 49-61
32. Torgerson J.S., Hauptman J., Boldrin M.N., and Sjöström L. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27 (2004) 155-161
33. Redmon J.B., Raatz S.K., Reck K.P., Swanson J.E., Kwong C.A., Fan Q., et al. One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial. Diabetes Care 26 (2003) 2505-2511
34. Jayagopal V., Kilpatrick S., Holding S., Jennings E., and Atkin S.L. Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J Clin Endocrinol Metab 90 (2005) 729-733
35. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GE, eds. Polycystic ovary syndrome. In: Hershman SM, series ed. Current issues in endocrinology and metabolism. Boston, MA: Blackwell, 1992:377-84.
36. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome PCOS. Hum Reprod 19 (2004) 41-47
37. Morley J.E., Patrick P., and Perry III H.M. Evaluation of assays available to measure free testosterone. Metabolism 5 (2002) 554-559
38. Matthews D., Hosker J., Rudenski A., Naylor B., Treacher D., and Turner R. Homeostasis model assessment: insulin resistance and ß-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
39. Katz A., Nambi S.S., Mather K., Baron A.D., Follmann D.A., Sullivan G., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85 (2000) 2402-2410
40. Lemieux S., Prud'homme D., Nadeau A., Tremblay A., Bouchard C., and Despres J.P. Seven-year changes in body fat and visceral adipose tissue in women. Associations with indexes of plasma glucose-insulin homeostasis. Diabetes Care 19 (1996) 983-991
41. Jayagopal V., Kilpatrick S., Holding S., Jennings E., and Atkin S.L. The biological variation of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 87 (2002) 1560-1562
42. Diamanti-Kandarakis E., Kouli C., Alexandraki K., and Spina G. Failure of mathematical models to accurately assess insulin resistance in lean, overweight or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 1273-1276
43. Pasquali R., Fabbri R., Venturoli S., Paradisi R., Antenucci D., and Melchionda N. Effect of weight loss and antiandrogenic therapy on sex hormone blood levels and insulin resistance in obese patients with polycystic ovaries. Am J Obstet Gynecol 154 (1986) 139-144
44. Panidis D., Macut D., Farmakiotis D., Kourtis A., Diamanti-Kandarakis E., Zournatzi-Koiou V., et al. Indices of insulin sensitivity, beta cell function and serum proinsulin levels in the polycystic ovary syndrome. Eur J Obstet Gynecol 127 (2006) 99-105
45. Ehrmann D.A., Barnes R.B., and Rosenfield R.L. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 16 (1995) 322-353
46. Jonard S., and DeWailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 10 (2004) 107-117